Immune dysregulation is an key component of the pathophysiology in various infections. In this section at the moment is the research data from Milken Institute on all COVID therapeutics.
New recently in #nature an article discussing current therapeutic options and the pathways involved in cell and chemical messenger regulation in the immune system a key part of managing acute to chronic pathology.
#amazingteam collation by
Frank L. van de Veerdonk et al Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands
Various studies indicate IL-1–IL-6 axis as key #signaling_pathways mediators in the SARS-CoV-2-induced hyperinflammatory reaction.
Also in severe COVID-19, low HLA-DR being the key molecules expressed on antigen presenting cells on circulating monocytes showed normal cytokine activity (affected in immunosuppressive disorderes). Cytokine regulation and expression remains a key marker of immune system cells largely awaiting further research.
HLA -DR is also expressed on other cell types.
Authors suggest that #covid is associated with a marked decrease in circulating CD4+ and CD8+ T cells similar to sepsis-associated lymphopenia which is indicated by current research. Helper and cytotoxic T cell understanding are key players in the longer term immune response.
In addition to this reduction in #lymphocyte numbers, their function and capacity to release type II #interferons is also severely affected in patients with severe COVID-19.
In discussion this article looks at the overview of current therapeutics which will all perform key parts in ongoing clinical treatment decisions.
1. #Polyclonal convalescent plasma
2. #antibodies -spike protein monoclonal antibodies
4. #Kinase inhibitors
5. #Anti-cytokine bioactive molecules
6. #Anti-complement treatment
8. #Kallikrein–kinin inhibitors
Note this post is not an endorsement of therapeutics. Article has further details. #chemical #medical #immunehealth